N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine: NPS-568 is the ((R), HCl salt)-isomer; calcimimetic compound and calcium-sensing receptor agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 158797 |
| CHEMBL ID | 292376 |
| SCHEMBL ID | 311950 |
| MeSH ID | M0427953 |
| PubMed CID | 158796 |
| CHEMBL ID | 2107572 |
| SCHEMBL ID | 1178446 |
| MeSH ID | M0427953 |
| Synonym |
|---|
| nps r568 |
| gtpl718 |
| benzenepropanamine, 2-chloro-n-(1-(3-methoxyphenyl)ethyl)-, (r)- |
| tecalcet |
| r 568 |
| tecalcet [inn] |
| (r)-2-chloro-n-(1-(3-methoxyphenyl)ethyl)benzenepropanamine |
| nps r 568 |
| nps-r568 |
| CHEMBL292376 , |
| [3-(2-chloro-phenyl)-propyl]-[(r)-1-(3-methoxy-phenyl)-ethyl]-amine |
| bdbm50299670 |
| (r)-3-(2-chlorophenyl)-n-(1-(3-methoxyphenyl)ethyl)propan-1-amine |
| 3-(2-chlorophenyl)-n-[(1r)-1-(3-methoxyphenyl)ethyl]propan-1-amine |
| 148717-54-8 |
| 8i16yle4us , |
| unii-8i16yle4us |
| NCGC00344508-01 |
| bdbm50432960 |
| SCHEMBL311950 |
| DTXSID90164084 |
| (r)-n-(3-methoxy-alpha-phenylethyl) -3-(2-chlorophenyl)-1-propylamine |
| ZVQUCWXZCKWZBP-CQSZACIVSA-N |
| Q27088954 |
| 9ig , |
| benzenepropanamine, 2-chloro-n-[(1r)-1-(3-methoxyphenyl)ethyl]- |
| AKOS040850283 |
| D06020 |
| tecalcet hydrochloride (usan) |
| 177172-49-5 |
| norcalcin (tn) |
| r-568 |
| nps r-568 |
| nps-r-568 |
| n-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine |
| tecalcet hydrochloride |
| 3-(2-chlorophenyl)-n-[(1r)-1-(3-methoxyphenyl)ethyl]propan-1-amine hydrochloride |
| norcalcin |
| tecalcet hcl |
| benzenepropanamine, 2-chloro-n-((1r)-1-(3-methoxyphenyl)ethyl)-, hydrochloride |
| krn 568 |
| tecalcet hydrochloride |
| 3-(2-chlorophenyl)-n-((1r)-1-(3-methoxyphenyl)ethyl)propan-1-amine hydrochloride |
| tecalcet hydrochloride [usan] |
| unii-3hp28r98lc |
| 3hp28r98lc , |
| 3-(2-chlorophenyl)-n-((1r)-1-(3-methoxyphenyl)ethyl)propan-1-amine hydrochloride |
| krn-568 |
| CHEMBL2107572 |
| npsr-568 |
| r 568 hydrochloride |
| smr004701455 |
| MLS006010765 |
| SCHEMBL1178446 |
| 2-chloro-n-[(1r)-1-(3-methoxyphenyl)ethyl]-benzenepropanamine hydrochloride |
| AKOS024457812 |
| DTXSID10170263 |
| AS-73997 |
| [3-(2-chlorophenyl)propyl][(1r)-1-(3-methoxyphenyl)ethyl]amine hydrochloride |
| tecalcet(hydrochloride) |
| J-011257 |
| 177172-49-5 (hcl) |
| (r)-3-(2-chlorophenyl)-n-(1-(3-methoxyphenyl)ethyl)propan-1-amine hydrochloride |
| mfcd16038895 |
| 2-chloro-n-[(1r)-1-(3-methoxyphenyl)ethyl]-benzenepropanaminehydrochloride |
| r 568 hcl |
| benzenepropanamine, 2-chloro-n-[(1r)-1-(3-methoxyphenyl)ethyl]-, hydrochloride (1:1) |
| HY-10167A |
| CS-0002492 |
| r-568 (hydrochloride) |
| Q27257225 |
| tecalcet (hydrochloride) |
| CHA17249 |
| (r)-3-(2-chlorophenyl)-n-(1-(3-methoxyphenyl)ethyl)propan-1-aminehydrochloride |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Our efforts to discover potent, orally bioavailable type II calcimimetic agents for the treatment of secondary hyperparathyroidism focused on the development of ring constrained analogues of the known calcimimetic R-568." | ( Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics. Davis, J; Fotsch, C; Harrington, PE; Henley, C; Lott, FD; Lu, JY; Morony, S; Poon, SF; Reagan, JD; St Jean, DJ; Yang, Y, 2009) | 0.35 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| " The first calcimimetic agent to be evaluated in clinical trials was R-568, but studies were discontinued because of its limited bioavailability and inconsistent pharmacokinetic profile." | ( Future role of calcimimetics in end-stage renal disease. Goodman, WG; Turner, SA, 2002) | 0.31 |
| " However, the low bioavailability of these first calcimimetics predicts a difficult clinical utilization." | ( Calcimimetic agents: review and perspectives. Frazão, JM; Ureña, P, 2003) | 0.32 |
| "Our efforts to discover potent, orally bioavailable type II calcimimetic agents for the treatment of secondary hyperparathyroidism focused on the development of ring constrained analogues of the known calcimimetic R-568." | ( Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics. Davis, J; Fotsch, C; Harrington, PE; Henley, C; Lott, FD; Lu, JY; Morony, S; Poon, SF; Reagan, JD; St Jean, DJ; Yang, Y, 2009) | 0.35 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " NPS R-568 rapidly increased plasma calcitonin levels to a peak at 10 to 20 min after oral dosing (ED(50) 40 mg/kg)." | ( Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats. Conklin, RL; Fox, J; Lowe, SH; Nemeth, EF; Petty, BA, 1999) | 0.3 |
| " To test this hypothesis, we compared two NPS R-568 dosing regimens in rats with chronic renal insufficiency induced by two intravenous injections of adriamycin." | ( Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Fox, J; Furuya, Y; Ishii, H; Nagano, N; Nemeth, EF; Wada, M, 2000) | 0.31 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PPM1D protein | Homo sapiens (human) | Potency | 46.6128 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 37.2212 | 0.0013 | 10.1577 | 42.8575 | AID1259252; AID1259253 |
| Interferon beta | Homo sapiens (human) | Potency | 46.6128 | 0.0033 | 9.1582 | 39.8107 | AID1347411 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Extracellular calcium-sensing receptor | Homo sapiens (human) | EC50 (µMol) | 0.1370 | 0.0200 | 0.2334 | 1.0000 | AID441276; AID738057 |
| Extracellular calcium-sensing receptor | Homo sapiens (human) | EC50 (µMol) | 0.0800 | 0.0200 | 0.2334 | 1.0000 | AID744122 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID45799 | Compound was evaluated for accumulation of [3H]- IP in CHO (CaSR) cells expressing rat cloned calcium sensing receptor | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | N1-Arylsulfonyl-N2-(1-aryl)ethyl-3-phenylpropane-1,2-diamines as novel calcimimetics acting on the calcium sensing receptor. |
| AID437457 | Inhibition of hyperparathyroidism in Sprague-Dawley rat pharmacodynamic model assessed as decrease in PTH levels at 30 mg/kg, po | 2009 | Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21 | Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics. |
| AID738057 | Positive allosteric modulation of human CaSR transfected in CHO cells after 5 hrs by luciferase reporter gene assay | 2013 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8 | New potent calcimimetics: I. Discovery of a series of novel trisubstituted ureas. |
| AID437453 | Mean residence time in Sprague-Dawley rat at 0.5 mg/kg, iv | 2009 | Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21 | Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics. |
| AID437455 | Cmax in Sprague-Dawley rat at 2 mg/kg, po | 2009 | Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21 | Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics. |
| AID437452 | Volume of distribution at steady state in Sprague-Dawley rat at 0.5 mg/kg, iv | 2009 | Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21 | Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics. |
| AID437454 | AUC in Sprague-Dawley rat at 2 mg/kg, po | 2009 | Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21 | Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics. |
| AID437456 | Oral bioavailability in Sprague-Dawley rat at 2 mg/kg | 2009 | Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21 | Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics. |
| AID437451 | Clearance in Sprague-Dawley rat at 0.5 mg/kg, iv | 2009 | Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21 | Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics. |
| AID441276 | Activity at human CaSR expressed in HEK293 cells assessed as calcium release by FLIPR assay | 2009 | Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21 | Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics. |
| AID45800 | Maximal stimulation of [3H]-inositol phosphates production in CHO cells expressing rat Calcium sensing receptor (CaSR) at 10 mM [Ca2+] | 2004 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12 | N2-benzyl-N1-(1-(1-naphthyl)ethyl)-3-phenylpropane-1,2-diamines and conformationally restrained indole analogues: development of calindol as a new calcimimetic acting at the calcium sensing receptor. |
| AID1346721 | Human CaS receptor (Calcium-sensing receptor) | 2012 | Endocrinology, Mar, Volume: 153, Issue:3 | Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. |
| AID1346721 | Human CaS receptor (Calcium-sensing receptor) | 1998 | Proceedings of the National Academy of Sciences of the United States of America, Mar-31, Volume: 95, Issue:7 | Calcimimetics with potent and selective activity on the parathyroid calcium receptor. |
| AID1346721 | Human CaS receptor (Calcium-sensing receptor) | 2015 | British journal of pharmacology, Jan, Volume: 172, Issue:1 | Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics. |
| AID744122 | Positive allosteric modulation of human CaSR expressed in CHO cells assessed as increase in intracellular calcium level after 5 hrs by luciferase reporter gene assay | 2013 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8 | New potent calcimimetics: II. Discovery of benzothiazole trisubstituted ureas. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (9.47) | 18.2507 |
| 2000's | 84 (49.70) | 29.6817 |
| 2010's | 54 (31.95) | 24.3611 |
| 2020's | 15 (8.88) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.26) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Trials | 4 (2.47%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Reviews | 35 (21.60%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Case Studies | 2 (1.23%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Observational | 1 (0.62%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| Other | 120 (74.07%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||